Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF) : A double-blind, randomised, placebo-controlled, phase 2b trial

Autor: Jürgen Behr, Antje Prasse, Michael Kreuter, Johannes Johow, Klaus F Rabe, Francesco Bonella, Reiner Bonnet, Christian Grohe, Matthias Held, Heinrike Wilkens, Peter Hammerl, Dirk Koschel, Stefan Blaas, Hubert Wirtz, Joachim H Ficker, Wolfgang Neumeister, Nicolas Schönfeld, Martin Claussen, Nikolaus Kneidinger, Marion Frankenberger, Simone Hummler, Nicolas Kahn, Silke Tello, Julia Freise, Tobias Welte, Petra Neuser, Andreas Günther, Nicolaus Schönfeld, Carmen Schade-Brittinger, Behnaz Aminossadati, Christian Nasemann, Soraya Yahiaoui, Christoph Dupuy Backofen, Maik Hahmann, Michael Wittenberg, Fotis Drakopanagiotakis, Daniel von der Beck, Stefanie Ghofrani, Sabine Heinemann, Ekaterina Krauss, Hella Rethorn, Andrea Koch, Gabriela Leuschner, Sandhya Matthes, Claus Neurohr, Tobias Veit, Katrin Milger-Kneidinger, Felix Herth, Julia Benstz, Thomas Bahmer, Heike Biller, Benjamin Waschki, Rosa-Marie Apel, Ulrich Costabel, Eva Börner, Thomas Wessendorf, Margret Arnrich, Lacramioara Ilie, Alexandra Wald, Hans-Jürgen Seyfarth, Christian Reinhardt, Atif Cinar, Markus Vogler, Siegfried Matthias Huhn, Jaqueline Richter, Ulrich Neff, Torsten Gerriet Blum, Silvan Vesenbeckh, Christian Boch, Hannes Semper, Andreas Wilke, Michael Pfeifer, Annette Schweda, Angelika Krill, Christian Lensch, Franziska Joa, Barbara Schröder, Annabel Plaßmeier, Stefan Baron, Klaus Peter Froehling

Publikováno v: Lancet Resp. Med. 9, 476-486 (2021)

Methods We did a multicentre, double-blind, randomised, placebo-controlled, parallel phase 2b trial (RELIEF) in 17 centres with expertise in ILD in Germany. Eligible participants were patients aged 18?80 years with progressive fibrotic ILD due to fou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4b6327b7d6687b4291da21ef340b24
https://www.ncbi.nlm.nih.gov/pubmed/33798455